D-0003-2021 Class II Terminated
FDA drug recall D-0003-2021 was initiated by Teva Pharmaceuticals USA on Sep 4, 2020 and is designated Class II. Reason for recall: Failed Stability Specifications: Below specification result for buprenorphine release rate. The recall status is terminated (terminated Aug 26, 2021). Affected quantity: 32,543 cartons.
Recall details
- Product Type
- Drugs
- Report Date
- Oct 7, 2020
- Initiation Date
- Sep 4, 2020
- Termination Date
- Aug 26, 2021
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 32,543 cartons
Product description
Buprenorphine Transdermal System 5 mcg/hour, 4 transdermal systems/4 disposal units per carton, Rx Only, Manufactured by: 3M Drug Delivery Systems, 19901 Nordhoff street, Northridge, CA 91324 USA, Manufactured for: Teva Pharmaceuticals USA Inc., North Wales, PA 19454, carton NDC: 0093-3656-40, patch NDC: 0093-3656-21.
Reason for recall
Failed Stability Specifications: Below specification result for buprenorphine release rate.
Distribution pattern
Nationwide in the U.S. and PR
Code information
Lot # 190017, exp. 02/2021; 190161, exp. 08/2021
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0003-2021
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026